RAPT Therapeutics (RAPT) Cash & Equivalents (2020 - 2024)
Historic Cash & Equivalents for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to $37.9 million.
- Therapeutics' Cash & Equivalents fell 2998.98% to $37.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $37.9 million, marking a year-over-year decrease of 2998.98%. This contributed to the annual value of $47.5 million for FY2023, which is 2190.73% up from last year.
- As of Q3 2024, Therapeutics' Cash & Equivalents stood at $37.9 million, which was down 2998.98% from $37.1 million recorded in Q2 2024.
- Therapeutics' Cash & Equivalents' 5-year high stood at $91.5 million during Q1 2020, with a 5-year trough of $20.2 million in Q3 2020.
- Over the past 5 years, Therapeutics' median Cash & Equivalents value was $38.9 million (recorded in 2022), while the average stood at $43.9 million.
- Data for Therapeutics' Cash & Equivalents shows a peak YoY increase of 19775.18% (in 2021) and a maximum YoY decrease of 7299.22% (in 2021) over the last 5 years.
- Therapeutics' Cash & Equivalents (Quarter) stood at $24.9 million in 2020, then dropped by 3.58% to $24.0 million in 2021, then skyrocketed by 62.09% to $38.9 million in 2022, then increased by 21.91% to $47.5 million in 2023, then fell by 20.17% to $37.9 million in 2024.
- Its last three reported values are $37.9 million in Q3 2024, $37.1 million for Q2 2024, and $45.3 million during Q1 2024.